For HR positive breast cancer patients, 76.0% of patients had received AI endocrine therapy, 40.0% had received fulvestrant endocrine therapy, and only 4 patients had received cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor treatment. Here, CDK4 is linked to breast cancer.